EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy

Neuro-Oncology

Volumn 10, Issue 6, 2008, Pages 946-957

  Holtkamp, Nikola ^a   Malzer, Elke ^a   Zietsch, Jan ^a   Okuducu, Ali Fuat ^b   Mucha, Jana ^c   Mawrin, Christian ^d   Mautner, Victor F ^e,f   Schildhaus, Hans Ulrich ^g   Von Deimling, Andreas ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

EGFR; ERBB2; MPNST; Targeted therapy; Tumor suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; TUMOR PROTEIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMOSOME 10; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NERVE SHEATH TUMOR; NEUROFIBROMA; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVE TUMOR; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENTIATION; GENE DOSAGE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; GENE DOSAGE; GENES, P16; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; NERVE SHEATH NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 60549108776     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-053     Document Type: Article

References (39)

1. Huson SM. Neurofibromatosis 1: a clinical and genetic overview. In Huson SM, Hughes RAC, eds. The Neurofibromatoses. London: Chapman and Hall Medical; 1994:160-203.
2. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA. 1990;87:5435-5439.
3. Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 1994;10:250-255.
4. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol. 1999;155:1855-1860.
5. Holtkamp N, Okuducu AF, Mucha J, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 2006;27:664-671.
6. Holtkamp N, Mautner V, Friedrich R, et al. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol Berl. 2004;107:159-168.
7. Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol. 2002;61:702-709.
8. Holtkamp N, Reuss DE, Atallah I, et al. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol. 2004;14:258-264.
9. DeClue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest. 2000;105:1233-1241.
10. Ling BC, Wu J, Miller SJ, et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell. 2005;7:65-75.
11. Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002;62:4507-4513.
12. Kindler-Rohrborn A, Kolsch BU, Fischer C, Held S, Rajewsky MF. Ethylnitrosourea-induced development of malignant schwannomas in the rat: two distinct loci on chromosome of 10 involved in tumor susceptibility and oncogenesis. Cancer Res. 1999;59:1109-1114.
13. Nakamura T, Ushijima T, Ishizaka Y, et al. Neu proto-oncogene mutation is specific for the neurofibromas in a N-nitroso-N-ethylurea-induced hamster neurofibromatosis model but not for hamster melanomas and human Schwann cell tumors. Cancer Res. 1994;54:976-980.
14. Carroll SL, Stonecypher MS. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. J Neuropathol Exp Neurol. 2005;64:1-9.
15. Stonecypher MS, Byer SJ, Grizzle WE, Carroll SL. Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene. 2005;24:5589-5605.
16. Coindre JM, Trojani M, Contesso G, et al. Reproducibility of a his- topathologic grading system for adult soft tissue sarcoma. Cancer. 1986;58:306-309.
17. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn. 2006;8:433-443.
18. Stoica G, Tasca SI, Kim HT. Point mutation of neu oncogene in animal peripheral nerve sheath tumors. Vet Pathol. 2001;38:679-688.
19. Bridge RS Jr, Bridge JA, Neff JR, Naumann S, Althof P, Bruch LA. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clin Pathol. 2004;57:1172-1178.
20. Plaat BE, Molenaar WM, Mastik MF, Hoekstra HJ, te Meerman GJ, van den Berg E. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: sporadic vs. neurofibromatosis-type-1-associated malignant schwannomas. Int J Cancer. 1999;83:171-178.
21. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer. 2004;39:29-36.
22. Perrone F, Tabano S, Colombo F, et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res. 2003;9:4132-4138.
23. Suzuki H, Sugimura H, Hashimoto K. p16INK4A in oral squamous cell arcinomas-a correlation with biological behaviors: immunohis-tochemical and FISH analysis. J Oral Maxillofac Surg. 2006;64:1617-1623.
24. Rodolfo M, Daniotti M, Vallacchi V. Genetic progression of metastatic melanoma. Cancer Lett. 2004;214:133-147.
25. Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch. 2002;440:610-615.
26. Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006;66:6546-6552.
27. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA. 1998;95:5246-5250.
28. Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2001;91:22-26.
29. Kwabi-Addo B, Giri D, Schmidt K, et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA. 2001;98:11563-11568.
30. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA. 2005;102:8573-8578.
31. Cohen JA, Yachnis AT, Arai M, Davis JG, Scherer SS. Expression of the neu proto-oncogene by Schwann cells during peripheral nerve development and Wallerian degeneration. J Neurosci Res. 1992;31:622-634.
32. Schlegel J, Muenkel K, Trenkle T, Fauser G, Ruschoff J. Expression of the ERBB2/neu and neurofibromatosis type 1 gene products in reactive and neoplastic Schwann cell proliferation. Int J Oncol. 1998;13:1281-1284.
33. Fernandes H, Cohen S, Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRVIII/DeltaEGFR) expressed in cancer cells. J Biol Chem. 2001;276:5375-5383.
34. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652-1654.
35. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446.
36. Fujita T, Doihara H, Kawasaki K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 2006;94:247-252.
37. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther. 2007;15:279-286.
38. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
39. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005;70:1568-1578.